[go: up one dir, main page]

UY37560A - COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS - Google Patents

COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS

Info

Publication number
UY37560A
UY37560A UY0001037560A UY37560A UY37560A UY 37560 A UY37560 A UY 37560A UY 0001037560 A UY0001037560 A UY 0001037560A UY 37560 A UY37560 A UY 37560A UY 37560 A UY37560 A UY 37560A
Authority
UY
Uruguay
Prior art keywords
mcl
inhibitor
combination
compound
taxan
Prior art date
Application number
UY0001037560A
Other languages
Spanish (es)
Inventor
Dale Porter
Ensar Halilovic
Leticia Maragno Ana
Chanrion Maïa
Olivier Geneste
Delphine Merino
James Whittle
VAILLANT François
Jane Visvader
Geoffrey Lindeman
Guillaume Lessene
Elisabetta Marangoni
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of UY37560A publication Critical patent/UY37560A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una combinación que comprende un inhibidor de MCL-1 y un compuesto taxano, y composiciones y usos de ésta.A combination comprising an MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

UY0001037560A 2017-01-06 2018-01-04 COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS UY37560A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443082P 2017-01-06 2017-01-06
EP17157779 2017-02-24
US201762527360P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
UY37560A true UY37560A (en) 2018-07-31

Family

ID=58158963

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037560A UY37560A (en) 2017-01-06 2018-01-04 COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS

Country Status (3)

Country Link
TW (1) TWI674898B (en)
UY (1) UY37560A (en)
WO (1) WO2018127575A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37843A (en) 2017-08-15 2019-03-29 Abbvie Inc MCL-1 MACROCYCLIC INHIBITORS AND METHODS OF USE
WO2020123994A1 (en) * 2018-12-14 2020-06-18 Prelude Therapeutics, Incorporated 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer
TW202114682A (en) * 2019-06-17 2021-04-16 法商施維雅藥廠 Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
AU2022291381A1 (en) 2021-06-11 2023-11-30 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
KR20240019330A (en) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Combination of MCL-1 inhibitor and antibody drug conjugate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684167B1 (en) * 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR3015483B1 (en) * 2013-12-23 2016-01-01 Servier Lab NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CN105311016A (en) * 2014-07-24 2016-02-10 中国科学院大连化学物理研究所 Anti-apoptosis Mcl-1 protein inhibitor, and applications thereof
FR3037956B1 (en) 2015-06-23 2017-08-04 Servier Lab NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037959B1 (en) 2015-06-23 2017-08-04 Servier Lab NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037958B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3037957B1 (en) 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3046792B1 (en) 2016-01-19 2018-02-02 Les Laboratoires Servier NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
WO2018127575A1 (en) 2018-07-12
TW201828942A (en) 2018-08-16
TWI674898B (en) 2019-10-21

Similar Documents

Publication Publication Date Title
AR121273A2 (en) ENZYMATIC INHIBITORS FOR USE IN MEDICINE AND PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM
CL2018003135A1 (en) Aromatic derivatives of sulfonamide.
UY37560A (en) COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
UY36151A (en) ? A PHARMACEUTICAL COMPOSITION THAT INCLUDES A 3-QUINASA DELTA PHOSFOINOSYTIDE INHIBITOR AND A CORTICOSTEROID ?.
CR20170099A (en) PIRROLOBENZODIAZEPINAS AND CONJUGADOS DE ANTIBERPOS-DISULFURO DE LAS SISAS
BR112017018276A2 (en) ? composition comprising peptidase and biotensive agent and their use?
CL2016003422A1 (en) Lysine specific demethylase-1 inhibitors
CL2016003423A1 (en) Lysine specific demethylase-1 inhibitors
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
CY1124338T1 (en) 3-PHOSPHOGLYCERATE DEHYDROGENATION INHIBITORS AND THEIR USES
SA519410093B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2019010643A (en) Forms and compositions of a mk2 inhibitor.
MD3347360T2 (en) Compounds useful for inhibiting ROR-gamma-t
ECSP19006687A (en) COMBINATION OF A BCL-2 INHIBITOR AND A MCL-1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS
CL2019001859A1 (en) Combination of an mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof.
CL2018001157A1 (en) Formulation of fixed dose combination, eflornithine and sulindac.
CY1124258T1 (en) COMPOUNDS USEFUL FOR INHIBITING ROR-γ-t
AR112217A1 (en) A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter
CL2018000489A1 (en) Forma de dosificacion oral que comprende el compuesto a (3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona); metodo para tratar, prevenir o controlar el cancer.
CU20170134A7 (en) 2-THIOPIRIMIDINONES
NO20161136A1 (en) Compounds and compositions for biofilm prevention
EA201991623A1 (en) COMBINATION MCL-1 INHIBITOR AND TAXANIC COMPOUND, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
EA201990305A1 (en) COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
BR112016022439A2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING CEFEPIM OR SULBACTAM
AR111177A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A JAK INHIBITOR

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20240506